Published in AIDS Weekly, October 23rd, 2006
GRACE (Gender, Race And Clinical Experience), a multicenter, open-label phase 3b trial, will compare gender differences in the efficacy, safety and tolerability of Prezista (darunavir) tablets administered with other antiretroviral agents over a 48-week treatment period. The study also will explore racial differences in treatment outcomes.
Prezista, co-administered with 100 mg...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-10-23)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.